Department of Internal Medicine, National Taiwan University Hospital, Taipei 100, Taiwan.
BMC Infect Dis. 2013 Apr 19;13:182. doi: 10.1186/1471-2334-13-182.
The present study was designed to investigate whether teicoplanin minimum inhibitory concentrations (MICs) of methicillin-resistant Staphylococcus aureus (MRSA) isolates play a role in the prognosis of patient with teicoplanin-treated MRSA bloodstream infection (BSI).
Between 1 January 2006 and 31 December 2009, adult patients with teicoplanin-treated MRSA BSI in two Taiwan medical centers were retrospectively enrolled. Their blood MRSA isolates were submitted for determination of MICs to various antibiotics and multi-locus sequence types. All-cause mortalities on Days 14 and 30, as well as clinical response at the end of teicoplanin therapy were treated as endpoints.
Two hundred seventy adult patients were enrolled and 210 blood MRSA isolates were available. Independent risk factors for un-favorable outcome at the end of teicoplanin therapy included septic shock (p < 0.0001) and an elevated C-reactive protein level (p = 0.0064). The independent risk factors for all-cause Day 14 mortality (13.0%) included the presence of auto-immune diseases (p = 0.0235), septic shock (p = 0.0253) and thrombocytopenia (p = 0.0018). The independent risk factors for all-cause Day 30 mortality (26.3%) included age (p = 0.0102), septic shock (p < 0.0001) and thrombocytopenia (p = 0.0059).
The current study didn't find a significant role for teicoplanin MICs in the prognosis of adult patients with teicoplanin-treated MRSA BSI.
本研究旨在探讨耐甲氧西林金黄色葡萄球菌(MRSA)分离株的替考拉宁最低抑菌浓度(MIC)是否与替考拉宁治疗的 MRSA 血流感染(BSI)患者的预后有关。
2006 年 1 月 1 日至 2009 年 12 月 31 日,在台湾的两个医学中心回顾性纳入接受替考拉宁治疗的 MRSA BSI 的成年患者。他们的血 MRSA 分离株被提交用于确定对各种抗生素和多位点序列类型的 MIC。将第 14 天和第 30 天的全因死亡率以及替考拉宁治疗结束时的临床反应作为终点。
共纳入 270 例成年患者,可获得 210 份血 MRSA 分离株。替考拉宁治疗结束时不良预后的独立危险因素包括感染性休克(p<0.0001)和 C 反应蛋白水平升高(p=0.0064)。全因第 14 天死亡率(13.0%)的独立危险因素包括自身免疫性疾病(p=0.0235)、感染性休克(p=0.0253)和血小板减少症(p=0.0018)。全因第 30 天死亡率(26.3%)的独立危险因素包括年龄(p=0.0102)、感染性休克(p<0.0001)和血小板减少症(p=0.0059)。
本研究未发现替考拉宁 MIC 对接受替考拉宁治疗的成人 MRSA BSI 患者预后有显著作用。